Treatment changes and actions after viral rebound.

<p>Treatment changes and actions after viral rebound.</p

Confirmed HIV-1 RNA ≥ 50 copies/mL by 48, 96, 144 and 192 weeks.

<p>SCT = short cycle therapy, CT = continuous therapy.</p

CONSORT diagram.

<p>SCT = short cycle therapy, CT = continuous therapy, LTFU = lost to follow-Up. The main trial phase finished when the last enrolled patient reached their 48 week visit, the extended follow-up phase finished when the last enrolled patient reached their 144 week follow-up visit. *One participant was unable to attend the randomisation visit due to a traffic accident and another participant was excluded due to unreliable attendance. †1 returned to CT for poor adherence, 1 changed to eviplera for simplification reasons. ‡2 only consented to routine data collection and were advised to return to CT, 1 changed to eviplera for simplification reasons. §1 only consented to routine data collection and were advised to return to CT, 1 returned to CT for poor adherence. CONSORT checklist is included in the Supporting information (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0196239#pone.0196239.s001" target="_blank">S1 File</a>).</p

Baseline characteristics.

<p>Baseline characteristics.</p

Virology, immunology and secondary endpoints over all follow-up.

<p>Virology, immunology and secondary endpoints over all follow-up.</p

Adverse events.

<p>Adverse events.</p

Time to confirmed HIV-1 RNA ≥ 50 copies/mL in the intent-to-treat analysis (adjusted Kaplan-Meier).

<p>SCT = short cycle therapy, CT = continuous therapy, HR = adjusted hazard ratio.</p